Blood Flow
Get access to the latest nutrition research
By becoming an Examine Plus member, you'll have access to all of the latest nutrition research on over 300 supplements across over 500 different health goals, outcomes, conditions, and more.
Human Effect Matrix
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what supplements affect blood flow.
| Grade | Level of Evidence [show legend] |
|---|---|
|
Robust research conducted with repeated double-blind clinical trials |
|
Multiple studies where at least two are double-blind and placebo controlled |
|
Single double-blind study or multiple cohort studies |
|
Uncontrolled or observational studies only |
|
Level of Evidence
?
The amount of high quality evidence. The more
evidence, the more we can trust the results.
|
Supplement |
Magnitude of effect
?
The direction and size of the supplement's impact on
each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
|
Consistency of research results
?
Scientific research does not always agree. HIGH or
VERY HIGH means that most of the scientific research agrees.
|
Notes |
|---|---|---|---|---|
|
|
Notable
|
Very High See all 20 studies |
Blood flow appears to be increased in the body very reliably as assessed by flow-mediated vasodilation (FMD) by around 2%, affecting both healthy and unhealthy people. There may also be an increase in arterial blood flow which is less reliable.
|
|
|
|
Notable
|
Very High See all 3 studies |
An improvement in nitric oxide dependent blood flow appears to occur following procyanidin supplementation which has been noted in both unhealthy persons as well as healthy controls; there does not appear to be a per se hypotensive effect either.
|
|
|
|
Minor
|
Low See all 6 studies |
May increase blood flow secondary to activating nitric oxide, but due to the unreliability of increasing nitric oxide there is also unreliability in how arginine increases blood flow
|
|
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
